NCT00885508Unknown2 期
A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 85
- 试验地点
- 25
- 主要终点
- Response (CR, mCR and Cri, according to IWG criteria for AML and IWG 2006 criteria for MDS) to the combination of lenalidomide and chemotherapy in adult high and int 2 MDS (IPSS) or AML with deletion 5q[31]
研究概览
简要总结
In this trial, the investigators will test the combination of escalating doses of chemotherapy (starting at relatively low dose) with lenalidomide in intermediate-2-or high risk MDS and AML with del 5 q31. It is hoped that this combined therapy will further increase response rate in intermediate-2-or high risk MDS and AML with del 5 q31, without major toxicity in comparison to historical results obtained with chemotherapy alone in the same subset of patients.
详细描述
Patients will receive lenalidomide combined to DNR- AraC chemotherapy. The first 31 patients will receive DNR 45 mg/m2/d, during 3 days, and AraC 200mg/m2/d CI during 7 days.
Progression or not to the next cohort DNR 60 mgm2/d x3d and AraC 200mg/m2d x7d , or on the contrary reduction to the lower cohort DNR 30 mgm2/d x3d and AraC 200mg/m2d x5d will be decided after inclusion of fixed numbers of patients ,after review of toxicity and efficacy by an independent safety review committee (SRC).
Efficacy would be defined as a response rate ≥50%. After inclusion of the first 31 patients, the SRC will choose the cohort dose the last 33 patients will receive, based on toxicity and efficacy criteria.
- Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . DNR 30-45-or 60 mg/m2 /d (depending on the cohort during 3 days (IV push)- AraC 200mg/m2/d during 5- 7 or 7 days (continuous infusion)+ G-CSF (lenograstim): 263 ug/d from day 9, until recovery from aplasia (maximum 30 days).
Evaluation will be performed after recovery from aplasia, on day 40 at the latest (with marrow aspirate and karyotype).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Must understand and voluntarily sign an informed consent form
- •Must be able to adhere to the study visit schedule and other protocol requirements
- •No contra indication to anthracycline based chemotherapy
- •Documented diagnosis of MDS, or CMML with WBC < 13,000/mm3 that meets IPSS criteria for intermediate-2 or high-risk disease, or AML with an associated del 5q[31] (the deleted chromosomal region must include 5q[31]), with or without additional cytogenetic abnormalities
- •Female subjects of childbearing potential must:
- •Understand that the study medication could have a potential teratogenic risk
- •Agree to use, and be able to comply with, effective contraception without interruption, 4 weeks before starting study drug, throughout study drug therapy (including dose interruptions) and for 4 weeks after the end of study drug therapy, even if she has amenorrhoea. This applies unless the subject commits to absolute and continued abstinence confirmed on a monthly basis. The following are effective methods of contraception:
- •Implant, Levonorgestrel-releasing intrauterine system (IUS) (prophylactic antibiotics should be considered at the time of insertion particularly in patients with neutropenia due to risk of infection) , Medroxyprogesterone acetate depot, Tubal sterilization, Ovulation inhibitory progesterone-only pills (i.e., desogestrel), Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses.
- •Combined oral contraceptive pills are not recommended. If a subject was using combined oral contraception, she must switch to one of the methods above. The increased risk of VTE continues for 4 to 6 weeks after stopping combined oral contraception.
- •Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/ml not more than 3 days from the start of study medication once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence.
- •Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization. These tests should be performed not more than 3 days before the start of next treatment. This requirement also applies to women of childbearing potential who practice complete and continued abstinence
- •Male subjects must:
- •Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study therapy if their partner is of childbearing potential and has no contraception.
- •Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.
- •All subjects must:
- •Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy.
- •Agree not to share study medication with another person and to return all unused study drug to the investigator
排除标准
- •Pregnant or lactating females.
- •Contra indication to anthracycline based chemotherapy.
- •Proliferative (WBC ≥ 13,000/mL) CMML.
- •Prior ≥ grade-2 NCI CTCAE (v 3.0) allergic reaction to thalidomide.
- •Prior desquamating (blistering) rash while taking thalidomide.
- •Prior history of malignancy other than MDS unless the subject has been free of disease for ≥ 5 years.
- •Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 28 days .
- •Less than 6 months since prior allogeneic bone marrow transplantation.
- •Less than 3 months since prior autologous bone marrow or stem cell transplantation.
- •Recombinant human erythropoietin (rHuEPO) therapy received within 28 days.
- •Known HIV-1 positivity.
- •Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he or she participates in the study.
- •Creatinine Clearance< 50 ml/min
- •Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 3.0 x upper limit of normal (ULN)
- •Serum total bilirubin > 1.5 mg/dL (expect for unconjugated hyperbilirubinemia due to Gilbert's disease or secondary to MDS).
- •Subjects with ≥ grade-2 neuropathy
研究组 & 干预措施
Aracytidine, Daunaurubicine, Lenalidomide
Experimental
干预措施: Lenalidomide (Drug)
结局指标
主要结局
Response (CR, mCR and Cri, according to IWG criteria for AML and IWG 2006 criteria for MDS) to the combination of lenalidomide and chemotherapy in adult high and int 2 MDS (IPSS) or AML with deletion 5q[31]
时间窗: At the end of induction
次要结局
- Duration of response(At 1 and 2 years)
- Survival and safety of the combination of lenalidomide and chemotherapy(At 1 and 2 years)
- Progression to AML(At 1 and 2 years)
研究者
研究点 (25)
Loading locations...
相似试验
撤回
2 期
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerEstrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeRecurrent Breast CarcinomaTriple Negative Breast CancerMetastatic Breast CancerNCT03644589University of Washington
招募中
2 期
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.Carcinoma, HepatocellularNCT06349980Shanghai Henlius Biotech117
终止
2 期
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate CancerProstate CancerNCT00780975PharmaMar8
已完成
1 期
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromesAcute Myelogenous LeukemiaMyelodysplastic SyndromeNCT02296242BioMed Valley Discoveries, Inc53
撤回
2 期
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder CancerCancer of the Bile DuctGallbladder CancerNCT00386516Galectin Therapeutics Inc.